Fetroja Approved for Nosocomial Pneumonia in US

September 30, 2020
Shionogi said on September 29 that the US FDA has granted approval for its novel antibiotic Fetroja (cefiderocol) for an additional indication of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The drug is newly indicated for the treatment...read more